menu
    • menu
    [{"orgOrder":0,"company":"Shaperon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Taurodeoxycholic Acid","moa":"NLRP3","graph1":"Dermatology","graph2":"Phase II","graph3":"Shaperon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Shaperon \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shaperon \/ Inapplicable"},{"orgOrder":0,"company":"Hudson Therapeutics","sponsor":"Shaperon","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Taurodeoxycholic Acid","moa":"NLRP3","graph1":"Dermatology","graph2":"Phase II","graph3":"Hudson Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hudson Therapeutics \/ Shaperon","highestDevelopmentStatusID":"8","companyTruncated":"Hudson Therapeutics \/ Shaperon"}]

    Find Clinical Drug Pipeline Developments & Deals for Taurodeoxycholic Acid

    Menu

    Taurodeoxycholic Acid

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Hudson Therapeutics

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            Hudson Therapeutics

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Taurodeoxycholic Acid

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Shaperon

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hudson Therapeutics Starts Phase 2b Trial for NuGel

                            Details : NuGel, a first-in-class topical inflammasome inhibitor, which is being evaluated for the treatment of mild to moderate atopic dermatitis.

                            Product Name : NuGel

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 10, 2025

                            Lead Product(s) : Taurodeoxycholic Acid

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Shaperon

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Shaperon

                            South Korea arrow
                            Pharma Live Expo
                            Not Confirmed

                            Shaperon

                            South Korea arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Taurodeoxycholic Acid

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Shaperon Enrolls First Patient in Phase 2 U.S. Trial for Atopic Dermatitis Therapy 'Nugel'

                            Details : NuGel® is a gel type atopic dermatitis drug candidate, inhibiting NLRP3 inflammasome through GPCR19-P2X7 modulation. Its active pharmaceutical ingredient called HY209.

                            Product Name : Nugel

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 18, 2024

                            Lead Product(s) : Taurodeoxycholic Acid

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth